Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zofia Zukowska-Grojec is active.

Publication


Featured researches published by Zofia Zukowska-Grojec.


Annals of the New York Academy of Sciences | 1990

Neuropeptide Y Receptor Subtypes, Y1 and Y2

Claes Wahlestedt; Lars Grundemar; R. Håkanson; Markus Heilig; Gregory H. Shen; Zofia Zukowska-Grojec; Donald J. Reis

Heterogeneity among NPY (and PYY) receptors was first proposed on the basis of studies on sympathetic neuroeffector junctions, where NPY (and PYY) can exert three types of action: 1) a direct (e.g., vasoconstrictor) response; 2) a postjunctional potentiating effect on NE-evoked vasoconstriction; and 3) a prejunctional suppression of stimulated NE release; the two latter phenomena are probably reciprocal, since NE affect NPY mechanisms similarly. It was found that amidated C-terminal NPY (or PYY) fragments, e.g., NPY 13-36, could stimulate selectively prejunctional NPY/PYY receptors, which were termed Y2-receptors. Consequently, the postjunctional receptors which were activated poorly by NPY/PYY fragments, were termed Y1-receptors. Later work has indicated that the Y2-receptor may occur postjunctionally in selected sympathetic effector systems. The central nervous system appears to contain a mixture of Y1- and Y2-receptors as indicated by functional as well as binding studies. For instance, NPY and NPY 13-36 produced diametrically opposite effects on behavioral activity, indicating the action of the parent peptide on two distinct receptors. Cell lines, most importantly neuroblastomas, with exclusive populations of Y1- or Y2-receptors, have been characterized by binding and second messenger studies. In this work, selective agonists for the two receptor subtypes were used. Work of many investigators has formed the basis for subclassifying NPY/PYY effects being mediated by either Y1- or Y2-receptors. A preliminary subclassification based on effects of NPY, PYY, fragments and/or analogs is provided in Table 6. It is, however, to be expected that further receptor heterogeneity will be revealed in the future. It is argued that mast cells possess atypical NPY/PYY receptors. The histamine release associated with stimulation of the latter receptors may, at least in part, underlie the capacity of NPY as well as of short C-terminal fragments to reduce blood pressure. Fragments, such as NPY 22-36, appear to be relatively selective vasodepressor agents because of their weak vasopressor properties.(ABSTRACT TRUNCATED AT 400 WORDS)


Annals of the New York Academy of Sciences | 1995

Neuropeptide Y. A novel sympathetic stress hormone and more.

Zofia Zukowska-Grojec

Several lines of evidence suggest that NPY is a neurotransmitter and neurohormone intricately involved in stress responses of the body, and as such should be considered a stress molecule. Thus, circulating plasma NPY levels are increased by stress particularly if it is severe or prolonged. Stress stimulates the release of NPY from the sympathetic nerves and the adrenal medulla (in some species also from platelets), and in addition, modulates NPY inactivation. Stress-induced plasma NPY levels may reach the concentrations that are vasoconstrictive per se in addition to potentiating the actions of catecholamines. Reciprocally, elevated circulating levels of catecholamines during stress appear to induce hypersensitivity of blood vessels to NPY. Consequently, the peptide may be responsible for stress-induced regional vasoconstriction (splanchnic, coronary, and cerebral) but also may exert other actions that may be a part of the stress response: facilitate platelet aggregation, leukocyte adhesion, and macrophage activation. NPY release and actions appear to be up-regulated by testosterone and down-regulated by estrogens; therefore, NPY may be of particular importance to stress-induced cardiovascular events in men. In addition to acute vasoconstrictive effects, NPY exerts chronic actions and stimulates vascular smooth muscle proliferation and vascular hypertrophy, and hence, may be a link between stress and potential chronic changes in blood vessels.


Archive | 1993

Origin and Actions of Neuropeptide Y in the Cardiovascular System

Zofia Zukowska-Grojec; Claes Wahlestedt

The cardiovascular system is richly innervated by sympathetic nerves containing norepinephrine (NE) and neuropeptide Y (NPY). Although NE is considered a major sympathetic neurotransmitter and a primary mediator of cardiovascular functions, the role of NPY is not yet well defined. Over the last several years, evidence has accumulated to indicate that NPY is a sympathetic cotransmitter mediating vasoconstriction independently of catecholamines, as well as being a modulator of autonomic cardiovascular responses (reviews: 1–4). NPY is also abundant in epinephrine-containing chromaffin cells of the adrenal medulla (5) and, under some conditions, may be secreted into the circulation as an adreno-medullary hormone (6). Finally, our (7) and other (8) recent data indicate the extraneuronal presence of NPY, e.g., in platelets, where it may subserve autocrine and paracrine functions in platelet—vascular interactions. Thus, there are at least three potential sources for circulating NPY: the sympathetic nerves, the adrenal medulla, and platelets. The first purpose of this chapter is to discuss the release of NPY from different sources into the cardiovascular system in humans and in other mammalian species, in physiological situations, such as stress, and in disease states, such as hypertension.


Regulatory Peptides | 1986

Neuropeptide Y and peptide YY mediate non-adrenergic vasoconstriction and modulate sympathetic responses in rats

Zofia Zukowska-Grojec; Markus Haass; Mohamed A. Bayorh

The modulation of cardiovascular sympathetic responses by neuropeptide Y (NPY) and peptide YY (PYY) was assessed in vivo, in pithed rats. Both peptides (0.02-2 nmol/kg) caused similar dose-dependent pressor responses, resistant to adrenergic blockade but antagonized by the calcium channel blocker, nifedipine. Only NPY, at the lowest dose, slightly accelerated heart rate (by 10 +/- 4 beats/min). At the pressor dose (0.6 nmol/kg) but not subpressor dose (0.2 nmol/kg), the increase in blood pressure induced by stimulation of the sympathetic outflow (ST: 0.3 Hz, 50 V, 1 min) was attenuated by PYY (by 40%), whereas ST-evoked tachycardia was reduced by NPY (by 35%). Neither NPY- nor PYY-pretreatment affected ST-induced increments in plasma norepinephrine (NE) and epinephrine concentrations. In addition, regional hemodynamic effects of NPY were studied in conscious rats instrumented with Doppler flow probes. The hypertension caused by NPY was attended by reflex bradycardia and marked rise in peripheral vascular resistance in renal (+ 233 +/- 59%), superior mesenteric (+ 183 +/- 65%) and hindquarter (+ 65 +/- 10%) circulation. The pattern of hemodynamic responses of NPY was similar to that of NE but, unlike the latter, persisted after adrenergic blockade.


Life Sciences | 1988

Differential plasma catecholamine and neuropeptide Y responses to acute stress in rats

Zofia Zukowska-Grojec; Maria Konarska; Richard McCarty

Neuropeptide Y (NPY) is a vasoconstrictor present in the sympatho-adrenomedullary system and may be co-released with norepinephrine (NE) and epinephrine (EPI) during sympathetic activation. We studied plasma NPY-immunoreactivity (-ir, radioimmunoassay) and catecholamine (radioenzymatic) responses during two acute stress paradigms that differ in character, intensity, and duration. The intermittent stress of footshock (0.75 and 1.5 mA, 0.5 sec duration, at 5-sec intervals, for 5 min) evoked intensity-dependent immediate increments in plasma NE and EPI, and a delayed NPY-ir response (+0.6 +/- 0.1 pmol/ml). Prolonged (60 min) immobilization caused greater increases in plasma NE and EPI levels and no changes in plasma NPY-ir until the end of the stress session (+0.3 +/- 0.1 pmol/ml). Plasma NPY-ir responses correlated with those of NE but not with EPI suggesting a sympathetic origin for the release of the peptide. Relatively greater NPY-ir responses to footshock than to immobilization may be consistent with a preferential release of the peptide by a bursting but not continuous mode of sympathetic activation. However, it may also be due to a differential activation of the sympathetic nerves and adrenal medulla by these two stress situations.


Naunyn-schmiedebergs Archives of Pharmacology | 1984

Estimation of intrasynaptic norepinephrine concentrations at vascular neuroeffector junctions in vivo

Irwin J. Kopin; Zofia Zukowska-Grojec; Mohamed A. Bayorh; David S. Goldstein

SummaryWe estimated vascular neuroeffector junctional norepinephrine concentrations and their relation to pressor responses by measuring plasma norepinephrine levels and blood pressure during sympathetic stimulation or norepinephrine infusion in pithed, vagotomized, α2-adrenoceptor blocked, adrenal-demedullated rats with and without uptake1 blockade by desipramine. For an increment in mean arterial pressure of 50 mm Hg, the estimated mean junctional norepinephrine concentration (ES50m) was about 7 nmol/l. Norepinephrine concentration gradients between the site of norepinephrine release and plasma appeared to be equal and reciprocal for sympathetic stimulation and for norepinephrine infusion. These gradients were reduced equally (by about two-thirds) after desipramine treatment, indicating that removal of both released and infused norepinephrine is mainly by neuronal uptake.


Journal of Cardiovascular Pharmacology | 1992

Cardiovascular Effects of ω-conopeptides in Conscious Rats: Mechanisms of Action

S. Scott Bowersox; Tejinder Singh; Laszlo Nadasdi; Zofia Zukowska-Grojec; Karen L. Valentino; Brian B. Hoffman

Summary: We examined the effects of ω-conopeptides, a novel class of neuronal voltage-gated calcium channel antagonists, on hemodynamic responses in rats. Intravenous (i.v.) injections of SNX-111 (ω-conopeptide MVIIA) dose-dependently decreased arterial blood pressure (BP) in conscious rats. Intracerebroventricular (i.c.v.) SNX- 111 injections (580 pmol) tended to increase BP and, after an initial decrease, to increase heart rate (HR). The doseresponse curve for SNX-111 administered i.v. in conscious rats was biphasic. Beginning at subdepressor doses, SNX-111 caused a long-lasting blockade of pressor responses elicited by sympathetic nerve stimulation in pithed animals but did not prevent increases in BP evoked by exogenously administered norepinephrine (NE). Pretreatment of rats with histamine antagonists partially blocked the hypotensive effects of the higher (870 and 2,900 nmol/kg) doses of SNX-111. Substitution of alanine for arginine at position 10 ([Ala10]-MV11A) markedly attenuated the histamine-mediated component of the vasodepressor response. Together, these findings indicate that SNX-111 administered i.v. decreases systemic BP by a combination of blockade of sympathetic neurotransmission and mast cell degranulation; the latter function appears to be dependent on the arginine residue in position 10 of the amino acid sequence of SNX-111


European Journal of Pharmacology | 1991

C-terminal neuropeptide Y fragments are mast cell-dependent vasodepressor agents

Gregory H. Shen; Lars Grundemar; Zofia Zukowska-Grojec; R. Håkanson; Claes Wahlestedt

Neuropeptide Y (NPY) is a well-established vasopressor agent present in sympathetic perivascular nerves. Recently, it was found that high doses of the peptide cause a biphasic pressor-depressor response upon intravenous administration. We now report that C-terminal NPY fragments (NPY-(18-36) and NPY-(22-36] given intravenously to conscious or pithed (areflexive) male Sprague-Dawley rats mimic the depressor component of the NPY-(1-36) response while displaying very low pressor activity. Additionally, we have found that the depressor component is blocked by the histamine H1-antagonist, mepyramine. Since the fragment, NPY-(22-36), was equipotent with NPY in inducing histamine release from isolated peritoneal mast cells, we conclude that short C-terminal NPY fragments, like NPY itself, act on mast cells to initiate histamine-mediated cardiovascular actions. Such actions may conceivably be accounted for by the abundance of positively charged amino acid residues in the C-terminus. Moreover, these fragments have little affinity for vascular NPY receptors, as indicated by their poor ability to displace iodinated NPY or peptide YY (PYY) from specific binding sites on vascular smooth muscle cells derived from rat aorta. In conclusion, we propose that short C-terminal NPY fragments, which contain several positively charged amino acid residues, retain the ability of NPY to release histamine from rat mast cells while being essentially devoid of direct vascular motor activity.


Regulatory Peptides | 1998

Endogenous neuropeptide Y mediates vasoconstriction during endotoxic and hemorrhagic shock.

Nadeem U Qureshi; Emmanuel K. Dayao; Shobha Shirali; Zofia Zukowska-Grojec; Gabriel J. Hauser

Neuropeptide Y (1-36), NPY, is a sympathetic vasoconstrictor whose activities in blood vessels is determined by the presence of vasoconstrictive Y1 receptors and the enzyme dipeptidyl peptidase IV (DPPIV), which converts NPY to non-vasoconstrictive peptides. While the role of the NPY system has been established during cold water stress, its role in hypotensive conditions has not; yet, exogenous NPY improves hemodynamics and survival in rats with endotoxic shock. We used a new selective non-peptidergic Y1 receptor antagonist, BIBP-3226, to determine the role of the endogenous NPY/Y1 system in endotoxic shock (induced by i.v. injection of 10 mg/kg of Escherichia coli lipopolysaccharide 0127:B8, LPS) and hemorrhagic shock (bleeding of 15 ml/kg over 1.5 min). Conscious rats received a bolus of BIBP-3226 or the vehicle 5 min before endotoxin challenge or induction of hemorrhage, followed by continuous infusion. Mean arterial pressure (MAP) at 5 min after LPS administration dropped in the control group by 15%, compared to 36% in the BIBP-3226-treated group (p < 0.01). Similarly, the hemorrhage-induced drop in MAP in the control group was 32% at 5 min, compared to 53% in the BIBP-treated rats (p < 0.01). Plasma NPY levels were unchanged in the endotoxic shock group, but were significantly elevated in the hemorrhagic shock group. BIBP-3226 pretreatment abrogated the increased plasma NPY levels after hemorrhagic shock. Endogenous NPY contributes to blood pressure recovery during endotoxic and hemorrhagic shock.


European Journal of Pharmacology | 1990

Biphasic blood pressure response to neuropeptide Y in anesthetized rats

Lars Grundemar; Claes Wahlestedt; Gregory H. Shen; Zofia Zukowska-Grojec; R. Håkanson

The effects of neuropeptide Y (NPY) on systemic arterial blood pressure and heart rate were studied in anesthetized intact and pithed rats. I.v. doses of NPY (0.3-30 nmol/kg) raised the mean arterial blood pressure dose dependently. At doses of greater than or equal to 3.0 nmol/kg, the initial pressor response was followed by a dose-dependent fall in blood pressure in intact and pithed rats. The depressor response was accompanied 1-2 min after the NPY injection by a slight increase in heart rate in pithed rats but not in intact rats, and 10 min after the injection by a decrease in heart rate in intact rats. After repeated injections of NPY, the depressor effect vanished, whereas the integrated pressor response over time was markedly enhanced. After pretreatment with the histamine H1-receptor antagonist, mepyramine, or with the histamine liberator, compound 48/80, the pressor response to NPY remained but the depressor response disappeared. We suggest that the marked fall in blood pressure can be attributed to NPY-evoked histamine release from mast cells.

Collaboration


Dive into the Zofia Zukowska-Grojec's collaboration.

Top Co-Authors

Avatar

Irwin J. Kopin

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Gabriel J. Hauser

George Washington University

View shared research outputs
Top Co-Authors

Avatar

Mohamed A. Bayorh

Morehouse School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nadav Zamir

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Adam K. Myers

Georgetown University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge